[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:graft-versus-host-disease":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":195,"states":196},"Graft Versus Host Disease",30,23,[8,16,23,30,37,43,49,55,61,67,73,79,85,91,97,103,109,115,121,127,133,138,144,150,157,163,169,176,182,189],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05664113","Feasibility, Safety, and Potential Efficacy of Fecal Microbiota Transplantation (FMT) for Gastrointestinal Dysfunction in Children Following Hematopoietic Cell Transplant (HCT).",[12],"Phase 1","RECRUITING","2026-08-26T02:18:36.226508Z","2026-07-24T01:27:14.925419Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07006506","A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant",[20],"Phase 2","2026-08-26T02:15:57.572488Z","2026-07-05T05:32:16.726154Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT06585774","A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease",[27],"Phase 3","2026-08-26T02:14:59.425132Z","2026-05-05T02:43:29.726098Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":35,"content_modified":36},"NCT06681922","A Phase I-II Study of High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Abatacept for the Prevention of Graft-Versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)",[34],"Phase 1\u002FPhase 2","2026-08-26T02:17:51.502023Z","2026-05-05T02:43:28.841969Z",{"nct_id":38,"title":39,"phases":40,"status":13,"updated_at":41,"content_modified":42},"NCT04337515","A Feasibility Study Using CLINIMACS® for Alpha\u002FBeta T-Cell Depletion in Stem Cell Transplant",[],"2026-08-26T02:17:38.215063Z","2026-05-05T02:43:27.481344Z",{"nct_id":44,"title":45,"phases":46,"status":13,"updated_at":47,"content_modified":48},"NCT07124078","A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)",[20],"2026-08-26T02:16:52.995882Z","2026-05-05T02:43:27.058151Z",{"nct_id":50,"title":51,"phases":52,"status":13,"updated_at":53,"content_modified":54},"NCT05675930","A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant",[20],"2026-08-26T02:17:30.145302Z","2026-05-05T02:35:31.755147Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":59,"content_modified":60},"NCT06392711","Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia",[12],"2026-08-26T02:16:49.565137Z","2026-05-05T02:43:27.953321Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT06450925","Vitamin A Supplementation in Allogeneic Stem Cell Transplantation.",[20],"2026-08-26T02:15:11.740957Z","2026-05-05T02:43:26.947287Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT07413172","Autologous Serum Tears With Hyaluronate vs Balanced Salt Solution for Moderate-to-Severe Dry Eye",[20],"2026-08-26T02:15:53.461103Z","2026-05-05T02:43:27.177155Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT04373057","Prebiotic Galacto-oligosaccharide and Acute GVHD",[34],"2026-08-26T02:19:18.331180Z","2026-05-05T02:43:28.370484Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT06991361","Ex Vivo-Expanded Regulatory T Cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic GVHD",[12],"2026-08-26T02:17:16.980188Z","2026-07-24T01:27:14.900742Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT06649201","Vulvovaginal Graft-versus-Host Disease: Diagnosis and Microbiome Evaluation",[],"2026-08-26T02:15:24.145250Z","2026-05-13T02:55:06.559847Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT05718791","CXCL9 and EASIX for Prediction of Acute Graft Versus Host Disease",[],"2026-08-26T02:18:57.189473Z","2026-05-13T02:55:06.372041Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT04946721","2177GCCC:ID'Ing tx Targets and Biomarkers for Ocular Surface Disease in Pt w\u002F oGVHD",[],"2026-08-26T02:17:05.172421Z","2026-05-13T02:55:06.275171Z",{"nct_id":104,"title":105,"phases":106,"status":13,"updated_at":107,"content_modified":108},"NCT04700657","The Prevalence of Hypoesthesia Related Keratitis in Ocular Graft Vs. Host Disease (GVHD) Patients",[],"2026-08-26T02:16:20.336282Z","2026-05-13T02:55:06.259558Z",{"nct_id":110,"title":111,"phases":112,"status":13,"updated_at":113,"content_modified":114},"NCT07235501","Kinetic Analysis of Immune Cells in Blood and Chronic Graft-Versus-Host Disease-Affected Tissues After Allogeneic Hematopoietic Cell Transplantation",[],"2026-08-26T02:17:41.695983Z","2026-05-13T02:55:06.680060Z",{"nct_id":116,"title":117,"phases":118,"status":13,"updated_at":119,"content_modified":120},"NCT06874283","Ocular Complications From Cancer Therapy - Patient Registry and Biobank",[],"2026-08-26T02:16:16.169331Z","2026-05-13T02:55:06.587419Z",{"nct_id":122,"title":123,"phases":124,"status":13,"updated_at":125,"content_modified":126},"NCT00106925","Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants",[],"2026-08-26T02:19:05.360997Z","2026-05-13T02:55:06.033699Z",{"nct_id":128,"title":129,"phases":130,"status":13,"updated_at":131,"content_modified":132},"NCT00128973","Evaluation of Patients With Immune Function Abnormalities",[],"2026-08-26T02:16:54.876240Z","2026-05-13T02:55:06.032743Z",{"nct_id":134,"title":135,"phases":136,"status":13,"updated_at":35,"content_modified":137},"NCT05236062","Impact of Exercise on the Complications of Corticosteroids in Patients With GVHD: the RESTART Trial",[],"2026-05-05T02:43:28.546031Z",{"nct_id":139,"title":140,"phases":141,"status":13,"updated_at":142,"content_modified":143},"NCT06910969","Multidisciplinary Intervention for Adults With Chronic Graft-versus-host Disease",[],"2026-08-26T02:17:14.343713Z","2026-05-05T02:43:28.010256Z",{"nct_id":145,"title":146,"phases":147,"status":13,"updated_at":148,"content_modified":149},"NCT06590285","Diagnostic Refinement and Educational Approaches in Managing Bone Marrow Transplantation",[],"2026-08-26T02:15:13.282904Z","2026-04-29T02:57:57.119828Z",{"nct_id":151,"title":152,"phases":153,"status":154,"updated_at":155,"content_modified":156},"NCT06995521","Vorinostat for Graft-versus-host Disease (GVHD) Prevention in Non-Malignant Adolescent and Young Adults (AYA) Population",[20],"NOT_YET_RECRUITING","2026-08-26T02:15:00.557154Z","2026-05-05T02:43:26.982723Z",{"nct_id":158,"title":159,"phases":160,"status":154,"updated_at":161,"content_modified":162},"NCT07728708","Effects of Axatilimab on Skin in Chronic Graft-versus-Host Disease",[],"2026-08-26T02:18:08.005333Z","2026-07-30T01:46:14.450690Z",{"nct_id":164,"title":165,"phases":166,"status":154,"updated_at":167,"content_modified":168},"NCT07381205","Assessing the Incidence of Transplant Associated Thrombotic Microangiopathy (TA-TMA) in Adult Patients Undergoing Allogeneic Stem Cell Transplant (SCT)",[],"2026-08-26T02:17:44.240289Z","2026-05-13T02:55:06.700451Z",{"nct_id":170,"title":171,"phases":172,"status":173,"updated_at":174,"content_modified":175},"NCT03369353","Precision Diagnostics in Inflammatory Bowel Disease, Cellular Therapy and Transplantation (The PREDICT Trial)",[],"ENROLLING_BY_INVITATION","2026-08-26T02:15:25.633039Z","2026-06-16T05:54:07.966256Z",{"nct_id":177,"title":178,"phases":179,"status":173,"updated_at":180,"content_modified":181},"NCT02422875","Comparative Autoantibody and Immunologic Cell Marker Study",[],"2026-08-26T02:17:54.420226Z","2026-06-16T05:54:07.952442Z",{"nct_id":183,"title":184,"phases":185,"status":186,"updated_at":187,"content_modified":188},"NCT06388564","A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease",[20],"ACTIVE_NOT_RECRUITING","2026-08-03T03:19:09.261668Z","2026-05-05T02:43:28.888003Z",{"nct_id":190,"title":191,"phases":192,"status":186,"updated_at":193,"content_modified":194},"NCT04044365","Pediatric cGVHD Symptom Scale",[],"2026-08-03T02:49:53.377789Z","2026-05-13T02:55:06.233352Z",[],[197,201,205,209,212,216,219,223,226,229,232,236,239,242,245,248,251,254,257],{"state":198,"count":199,"slug":200},"Maryland",8,"maryland",{"state":202,"count":203,"slug":204},"New York",7,"new-york",{"state":206,"count":207,"slug":208},"California",6,"california",{"state":210,"count":207,"slug":211},"Florida","florida",{"state":213,"count":214,"slug":215},"Massachusetts",5,"massachusetts",{"state":217,"count":214,"slug":218},"Pennsylvania","pennsylvania",{"state":220,"count":221,"slug":222},"Georgia",4,"georgia",{"state":224,"count":221,"slug":225},"Illinois","illinois",{"state":227,"count":221,"slug":228},"Tennessee","tennessee",{"state":230,"count":221,"slug":231},"Washington","washington",{"state":233,"count":234,"slug":235},"Arizona",3,"arizona",{"state":237,"count":234,"slug":238},"Colorado","colorado",{"state":240,"count":234,"slug":241},"District of Columbia","district-of-columbia",{"state":243,"count":234,"slug":244},"Michigan","michigan",{"state":246,"count":234,"slug":247},"New Jersey","new-jersey",{"state":249,"count":234,"slug":250},"North Carolina","north-carolina",{"state":252,"count":234,"slug":253},"Ohio","ohio",{"state":255,"count":234,"slug":256},"Texas","texas",{"state":258,"count":234,"slug":259},"Wisconsin","wisconsin"]